Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)

DOI: 10.1136/adc.2010.188946
Archives of Disease in Childhood, 2011, 96, 596-601.

#	Paper	IF	Citations
136	Current medical treatments for juvenile idiopathic arthritis. **2011**, 2, 60		16
135	Recent advances in medicines for children and neonates. **2011**, 4, 563-5		
134	Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases. *Archives of Disease in Childhood*, **2012**, 97, 561-3	2.2	13
133	Current world literature. **2012**, 27, 190-6		1
132	A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA). *Archives of Disease in Childhood*, **2012**, 97, 185-8	2.2	39
131	An international registry on autoinflammatory diseases: the Eurofever experience. *Annals of the Rheumatic Diseases*, **2012**, 71, 1177-82	2.4	121
130	Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. **2012**, 367, 2396-406		484
129	Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. **2012**, 367, 2385-95		577
128	A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. **2012**, 64, 557-67		147
127	Outcomes research in childhood autoimmune diseases. **2013**, 39, 921-33		5
126	Impact of the European paediatric legislation in paediatric rheumatology: past, present and future. *Annals of the Rheumatic Diseases*, **2013**, 72, 1893-6	2.4	21
125	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. *Annals of the Rheumatic Diseases*, **2013**, 72, 686-93	2.4	84
124	Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. *Annals of the Rheumatic Diseases*, **2013**, 72, 1503-9	2.4	11
123	Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. *Annals of the Rheumatic Diseases*, **2014**, 73, 1114-22	2.4	76
122	Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. *Annals of the Rheumatic Diseases*, **2014**, 73, 2168-73	2.4	87
121	Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. *Arthritis and Rheumatology*, **2015**, 67, 2759-70	9.5	56
120	Clinical trials in children. **2015**, 79, 357-69		148

119	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. *Annals of the Rheumatic Diseases*, **2015**, 74, 1110-7	2.4	195
118	Neonatal medicines research: challenges and opportunities. **2015**, 11, 1041-52		9
117	Improving care delivery and outcomes in pediatric rheumatic diseases. **2016**, 28, 110-6		22
116	Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. *Journal of Rheumatology*, **2016**, 43, 816-24	4.1	27
115	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. **2016**, 387, 671-678		124
114	Time to diagnosis in juvenile idiopathic arthritis: a french perspective. **2017**, 12, 43		19
113	Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease. **2017**, 186, 110-117.e11		26
112	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials	9.5	36
111	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology	9.5	33
110	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology	2.4	65
109	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Annals of the Rheumatic Diseases*, **2017**, 76, 782-791	2.4	24
108	Roles of Clinical Research Networks in Pediatric Drug Development. **2017**, 39, 1939-1948		11
107	Extrapolation or controlled trials in paediatrics: the current dilemma. *Archives of Disease in Childhood*, **2017**, 102, 949-951	2.2	8
106	Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials. **2017**, 5, 613-621		2
105	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. *Arthritis Care and Research*, **2017**, 69, 677-686	4.7	32
104	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. *Rheumatology*, **2017**, 56, 1884-1893	3.9	23
103	Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. *Pediatric Rheumatology*, **2017**, 15, 86	3.5	41
102	Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. *Arthritis and Rheumatology*, **2018**, 70, 1144-1154	9.5	33

101	The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 235-242	1
100	The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 59-66	
99	The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 51-58	
98	The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 227-233	
97	The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 395-402	3
96	The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 387-393	1
95	The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 363-369	
94	The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 107-113	
93	The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 243-250	1
92	The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 283-289	
91	The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 27-33	3
90	The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 99-105	
89	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 251-258	1
88	Update on outcome assessment in myositis. **2018**, 14, 303-318	55
87	Current and future perspectives in the management of juvenile idiopathic arthritis. **2018**, 2, 360-370	21
86	The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 275-282	
85	The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 347-354	
84	The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 371-377	

83	The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 19-26	2
82	The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 187-194	
81	The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 83-90	0
80	The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 115-122	
79	The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 147-153	
78	The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 179-186	
77	The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 211-218	2
76	The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 219-226	1
75	The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 171-178	1
74	The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 291-298	
73	The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 307-313	
72	The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 315-321	
71	The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 331-338	
70	The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 139-146	2
69	The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 91-98	
68	The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 43-49	5
67	The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 403-409	3
66	The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 35-42	5

65	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. **2018**, 38, 5-17		64
64	The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 131-138		
63	The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 163-169		
62	The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 155-161		5
61	The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 195-201		
60	The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 203-209		
59	The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 259-265		
58	The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 355-361		
57	The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 379-386		
56	The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 67-73		1
55	Paediatric research in Spain: Challenges and priorities. INVEST-AEP Platform. **2018**, 89, 314.e1-314.e6		
54	[Paediatric research in Spain: Challenges and priorities. INVEST-AEP Platform]. **2018**, 89, 314.e1-314.e6		2
53	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. *Arthritis Research and Therapy*, **2018**, 20, 285	5.7	41
52	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. *Annals of the Rheumatic Diseases*, **2018**, 77, 1710-1719	2.4	53
51	Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review. *Archives of Disease in Childhood*, **2018**, 103, 1067-1075	2.2	1
50	Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial. *Journal of Rheumatology*, **2018**, 45, 1173-1179	4.1	6
49	The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 75-82		4
48	The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 267-274		5

47	The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 299-306		3
46	The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 323-329		
45	The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 123-130		
44	The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). **2018**, 38, 339-346		
43	Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. *Annals of the Rheumatic Diseases*, **2018**, 77, 1558-1565	2.4	61
42	Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. *Arthritis Research and Therapy*, **2019**, 21, 125	5.7	17
41	The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. *Pediatric Rheumatology*, **2019**, 17, 24	3.5	8
40	Classification criteria for autoinflammatory recurrent fevers. *Annals of the Rheumatic Diseases*, **2019**, 78, 1025-1032	2.4	159
39	The Role of International Registries for Rare Autoinflammatory Diseases. **2019**, 253-265		0
38	Treatment of juvenile idiopathic arthritis: what's new?. **2019**, 31, 428-435		11
37	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. *Journal of Rheumatology*, **2019**, 46, 429-436	4.1	12
36	Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. *Clinical Rheumatology*, **2019**, 38, 563-575	3.9	18
35	Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. *Arthritis Care and Research*, **2020**, 72, 265-273	4.7	3
34	Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. *Arthritis Care and Research*, **2020**, 72, 1420-1430	4.7	11
33	Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. *RMD Open*, **2020**, 6,	5.9	5
32	A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis. *Rheumatology*, **2021**, 60, 2896-2905	3.9	1
31	Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. *Annals of the Rheumatic Diseases*, **2020**, 79, 1340-1348	2.4	48
30	Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. *Arthritis Care and Research*, **2021**, 73, 1264-1274	4.7	0

29	Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. *Arthritis Research and Therapy*, **2020**, 22, 211	5.7	2
28	Safety evaluations of adalimumab for childhood chronic rheumatic diseases. *Expert Opinion on Drug Safety*, **2020**, 19, 661-671	4.1	6
27	Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. *Pediatric Rheumatology*, **2020**, 18, 19	3.5	8
26	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. *Arthritis Research and Therapy*, **2020**, 22, 71	5.7	9
25	Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients. *Modern Rheumatology*, **2021**, 31, 226-234	3.3	7
24	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. *Arthritis and Rheumatology*, **2021**, 73, 336-346	9.5	7
23	Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. *Arthritis and Rheumatology*, **2021**, 73, 530-541	9.5	8
22	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. *Journal of Rheumatology*, **2021**, 48, 1073-1081	4.1	
21	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. *Rheumatology*, **2021**, 60, 4495-4507	3.9	3
20	Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. *Rheumatology*, **2021**,	3.9	2
19	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. *Rheumatology*, **2021**, 60, 4568-4580	3.9	5
18	Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials. *Pediatric Rheumatology*, **2021**, 19, 46	3.5	2
17	Outcome Scores in Pediatric Rheumatology. *Current Rheumatology Reports*, **2021**, 23, 23	4.9	2
16	Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa: An Open-Label, Randomized, Bayesian Noninferiority Trial. *Arthritis and Rheumatology*, **2021**, 73, 1673-1682	9.5	5
15	Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. *Rheumatology*, **2021**,	3.9	1
14	Juvenile Idiopathic Arthritis. **2017**, 265-288		4
13	Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa. *PLoS ONE*, **2015**, 10, e0120981	3.7	29
12	Recruitment and Retention in Pediatric Clinical Trials: Focus on Pediatric Research Networks in the US and EU. 455-471		

11	Needs and Research Priorities for Young People with Spinal Cord Lesion or Spina Bifida and Their Caregivers: A National Survey in Switzerland within the PEPSCI Collaboration.. *Children*, **2022**, 9,	2.8	0
10	Early Discontinuation, Results Reporting, and Publication of Pediatric Clinical Trials.. *Pediatrics*, **2022**,	7.4	0
9	Validation of the parent global assessment as a health-related quality of life measure in juvenile idiopathic arthritis: Results from ReACCh-Out. *Rheumatology*,	3.9	0
8	Pediatric health and life domain priorities: A national survey of people with spinal cord injury and their parents and caregivers. *Journal of Spinal Cord Medicine*, 1-13	1.9	
7	Development and external validation of a model predicting new-onset chronic uveitis at different disease durations in juvenile idiopathic arthritis.		
6	Emerging therapies for juvenile arthritis: agents in early clinical trials. 1-16		0
5	Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study. **2022**, 20,		0
4	Long-term Efficacy and Safety of Canakinumab in the Treatment of Systemic Juvenile Idiopathic Arthritis in Japanese Patients: Results from an Open-label Phase III Study.		0
3	Patients and parents satisfaction to improve patient care in JIA: factors determining acceptable symptom state measured with JAMAR.		1
2	Breaking down the fences among registries on Autoinflammatory diseases: the E-Merge project.		0
1	Juvenile idiopathic arthritis patients with positive family history of autoimmune thyroid disease might benefit from serological screening: analysis of the international Pharmachild registry. **2023**, 21,		0